Objective. To characterize circulating B-cell subpopulations of arthritis patients with <6 weeks of disease duration.
Introduction
RA is a chronic, systemic autoimmune disease of unknown aetiology affecting $1% of the world population. RA is characterized by symmetric polyarthritis associated with pain and swelling in multiple joints that, if left untreated, ultimately leads to joint destruction [1] .
The very early inflammatory reaction that occurs in the rheumatoid synovium is mainly constituted by neutrophils [2, 3] . However, this first inflammatory infiltrate quickly leads to increased expression of inflammatory cytokines, chemokines and adhesion molecules, inducing the recruitment of B cells, T cells and macrophages [4] [5] [6] . In fact, it is this secondary cell infiltrate that supports the persistence of the inflammatory response and mediates cartilage and bone destruction. Although RA has long been considered as a T-cell-centred disorder, recent evidence suggests that B cells do play an important role in the onset and perpetuation of this disease [7] . B cells function both as IL-producing cells and antigen presenting cells that activate T cells [8, 9] and are also responsible for the production of autoantibodies [10] [11] [12] , such as RF. RF can interact with FcgRIIIa (CD16) receptors on monocytes and macrophages inducing the production of TNF [13] . Moreover, B-cell depletion therapy with rituximab, a mAb directed to CD20, have confirmed the importance of these cells in established RA [14] . Several studies have shown that following B-cell depletion in patients with RA, there is clinical and serological improvement that parallels with a decrease in RF levels [15] . Despite the evidence for a critical role of B cells in established RA, the knowledge on the participation of these cells in the early phase of the disease is still scarce. In addition, the effect of commonly used DMARDs, such as MTX, on B cells is also largely unknown.
The major goal of this study is to characterize circulating B-cell subpopulations in very early RA (VERA) and in other very early arthritis (VEA) patients when compared with healthy donors, and also to evaluate whether corticosteroids and MTX therapies have an impact on the frequencies of these cell subsets.
Materials and methods

Patients
Blood samples were obtained from 46 untreated polyarthritis patients (Rheumatology Department, Hospital de Santa Maria, Lisbon) with <6 weeks of disease duration. Twenty-two of these patients later on fulfilled the ACR criteria for RA [16] . These patients were classified as VERA patients and further samples were collected at 4-6 weeks after starting a low dose of oral prednisone (5-10 mg) (Time 1) and 4 months after reaching the minimum effective dose of MTX, up to a maximum of 20 mg/week, which was needed to reduce the 28-joint disease activity score (DAS28) to <3.2 (Time 2) [17] . The baseline blood samples from VERA patients were compared with 24 VEA patients and 29 healthy donors who were used as controls. The HAQ [18] was applied to all patients and the DAS28 was calculated in all patients who fulfilled the ACR criteria for RA. The local ethics committee (Comissã o de É tica do Hospital de Santa Maria) approved the study and all patients signed an informed consent. Patient's management was done in accordance with the standard practice and the study was conducted in accordance with the Declaration of Helsinki as amended in Edinburgh (2000).
Antibodies
Immunophenotyping of B and T cells in peripheral blood and peripheral blood mononuclear cells (PBMC) samples was performed using matched combinations of anti-human murine mAbs conjugated to FITC, phycoerythrin (PE), peridinin chlorophyll protein (PerCP) or allophycocyanin (APC). Isotype control antibodies were used for each fluorophore. For B-cell analysis, combinations of anti-CD19 conjugated to PerCP (clone 4G7, BD Biosciences, San Jose, CA, USA) or APC (HIB19, eBioscience, San Jose, CA, USA), anti-IgD conjugated to FITC or PE (IA6-2, BD Biosciences) and anti-CD27 conjugated to PE or APC (O323, eBioscience) were used.
T cells were identified with anti-CD3 PerCP (SK7, BD Biosciences), anti-CD4 FITC (MEM-241, Immunotools, Friesoythe, Germany) and anti-CD8 APC (MEM-31, Immunotools).
Whole-blood staining Approximately 5 ml of whole blood was collected by venipuncture into tubes containing ethylenediamine tetraacetic acid. Erythrocytes were lysed with FACS Lysing Solution (BD Biosciences) and cells were stained, incubated for 20 min at 4 C, washed and stored in the dark at 4 C until analysed by flow cytometry. Frozen PBMC samples of patients were also used for staining protocol in order to establish the reproducibility of flow cytometry data from fresh and frozen samples. A total of 200 000 cells/sample were acquired with a FACSCalibur (BD Biosciences). Data were analysed with FlowJo (TreeStar, Stanford University, CA, USA). Absolute cell counts were calculated from differential leucocyte count determined at each time point for all patients.
PBMC isolation
PBMCs were isolated from 20 ml of heparinized whole blood following density gradient centrifugation with Percoll (Amersham, Stockholm, Sweden). Cellular viability was estimated with Trypan Blue (Sigma, St. Louis, USA). Cells were frozen in 1 ml/10 7 cells RPMI-1640 (Invitrogen, Paisley, UK), 40% fetal calf serum (Invitrogen), 10% dimethyl-sulphoxide (Sigma) and stored at À80 C until further use.
Measurement of autoantibodies
RFs (IgM, IgG and IgA) and anti-cyclic citrullinated peptide (anti-CCP) were determined at baseline in all patients and also at Times 1 and 2 for VERA patients. IgM-RF, IgG-RF and IgA-RF were measured in the serum by IMTEC Autoimmune Diagnostics ELISA test system kits (Human GmbH, Wiesbaden, Germany) according to the manufacturer's instructions and samples were processed using a ChemWell 2910 automated analyser. Serum levels of anti-CCP were measured by ELIA CCP test system (Phadia GmbH, Freiburg, Germany) and samples were analysed using an ImmunoCAP 100 instrument.
Statistical analysis
Statistical differences were determined using one-way analysis of variance and Bonferroni's multiple comparison tests using GraphPad Prism (GraphPad, San Diego, CA, USA). For populations that did not follow Gaussian distribution, the Kruskal-Wallis non-parametric test was used. Differences were considered statistically significant for P < 0.05.
Results
Disease assessment and autoantibody production A total of 46 polyarthritis patients with <6 weeks of disease duration were evaluated. Twenty-two patients, www.rheumatology.oxfordjournals.org 18 females and 4 males, with a mean age of 46.9 (16.3) years (range 23-77 years) fulfilled the ACR criteria for RA later on and were classified as VERA patients. At baseline, 10 of the VERA patients were RF positive, 6 of whom had anti-CCP antibodies (analysis performed up to 6 weeks after onset). All the RF-negative patients simultaneously lacked anti-CCP antibodies. A quantitative analysis of the production of RF and anti-CCP was also performed (Table 1) . Patients with detectable levels for RF were positive for both IgM-and IgG-RF. Only two of the patients were positive for IgA-RF (data not shown). Interestingly, although not statistically significant, the mean levels of IgG-RF and anti-CCP decreased with therapy ( Table 1 ). After therapy with corticosteroids and MTX, a clinical response associated with the decrease in DAS28 score (P = 0.0019 and P = 0.0068, respectively) could be observed. In the remaining group of 24 other VEA subjects, 16 females and 8 males, with a mean age of 44.8 (18.5) years (range 19-87 years), patients were later classified as having SLE (4), crystal-induced arthritis (3), PsA (2), colon adenocarcinoma (1), multiple myeloma (1), PMR (1), arthritis associated with HIV infection (1), arthritis associated with Crohn's disease (1), unremitting undifferentiated arthritis (2), unremitting ReA (2) and 6 patients entered spontaneously into remission before 3 months of follow-up, remaining without a specific diagnosis and were thus classified as a self-limited form of arthritis. For this study, 29 healthy controls, 22 females and 7 males, with a mean age of 39.8 (13.6) years (range 22-63 years) were also analysed. and plasma cells (CD19 + CD27 high ) from VERA patients were compared with the same populations of healthy donors (Fig. 1) . The frequency of total B cells at baseline was similar between VERA patients and healthy controls, being the average of circulating B cells gated in total lymphocytes of 11.69% (6.85) and 11.37% (5.69), respectively ( Fig. 2A) . Furthermore, corticosteroids and MTX did not affect the frequency of total B cells. Also, the analysis of absolute cell numbers of total B cells confirmed this result ( Fig. 2A) . Naïve B cells were significantly higher in VERA patients without treatment when compared with controls ( Fig. 2B) and their percentages tended to return to normal values after corticosteroid and MTX treatment, although this effect was not statistically significant. In addition, the analysis of absolute cell counts of this B-cell subpopulation did not show any statistically significant difference between groups (Fig. 2B ). Both controls and VERA patients had comparably very low levels (<3%) of circulating plasma cells (Fig. 2C) . VERA patients had significantly lower frequencies of pre-switch memory B cells when compared with controls ( Fig. 3A) , irrespective of therapy. Importantly, this observation was also confirmed by a decrease in the absolute numbers of this B-cell subpopulation (Fig. 3B) . In contrast, no statistically significant differences were observed in post-switch memory B cells between VERA patients and controls (Fig. 3C) . A lower percentage of total memory B cells was observed in untreated VERA patients as compared with controls ( Fig. 3D ) and no effect after MTX treatment was observed. Furthermore, no correlation was found between the age of the patients and the percentages or absolute cell numbers of pre-switch and total memory B cells (data not shown). No correlation was found between DAS28 and the percentages or absolute cell numbers of pre-switch and total memory B cells at all time points (data not shown). Moreover, in order to verify whether an association existed between peripheral B-cell abnormalities, particularly in the memory B-cell pool, with the presence or absence of autoantibodies in the serum, circulating B-cell subsets were analysed at baseline comparing seronegative and seropositive VERA patients both for RF (IgM and IgG) and anti-CCP, but no statistically significant differences were observed (data not shown).
We also investigated differences between VERA patients and controls in circulating T cells, namely total Although 22 VERA patients were selected for this study, 5 patients were lost to follow-up, technical problems occurred with the processing of the samples in 4 patients and 3 patients missed one of the appointments. Thus, the number of patients considered at each time point (n) is indicated together with the appropriate data in all the figures.
VEA patients have a diminished pre-switch memory B-cell subset at baseline Other very early polyarthritis patients evaluated with <6 weeks of disease duration, who later were diagnosed as having types of arthritis other than RA, were followed in this study for comparison with VERA patients. VEA patients did not show any statistically significant difference in both frequencies and absolute numbers of total B cells (Fig. 4A) , naïve B cells (Fig. 4B ) or plasma cells (Fig. 4C) when compared with controls. However, similar to what was observed in VERA patients, VEA patients had a significantly (P < 0.05) lower frequency of pre-switch and total memory B cells as compared with controls (Fig. 5) . Interestingly, the frequency of pre-switch memory B cells was similar in both VEA and VERA patients without treatment, being the average of 6.94% (4.64) and 5.33% (3.82), respectively (Fig. 5A) . The analysis of absolute numbers of pre-switch memory B cells in the peripheral blood of VEA patients confirmed a statistically significant reduction in this B-cell subpopulation (Fig.  5B) . No other statistically significant results were obtained with post-switch memory B cells (Fig. 5C) B cells carried somatically hypermutated antibodies, which indicates that this population is in fact a memory B-cell subset. However, the functional differences and characteristics between the two memory B-cell subpopulations remain to be clearly elucidated. In a study performed by Shi et al. [28] , data were obtained that helped to clarify the differences between memory B-cell subsets.
FIG. 1 B-cell analysis by flow cytometry.
A region (gate) was defined around total lymphocytes in peripheral blood, depending upon cell size (forward scatter) and granularity (side scatter). Total B cells were identified based on the expression of the cell surface marker CD19, and its subpopulations were classified according to IgD and CD27 expression in healthy controls (A) and patients (B class-switched memory B cells that mainly express surface IgG and IgA isotypes. These findings were reinforced by the discovery that activation-induced cytidine deaminase, which is essential for class-switch recombination process [29, 30] , was spontaneously expressed in IgD À CD27 + B cells, but was not found in IgD + CD27
+ memory B cells [28] . CD27 is now an important marker for analysis of B-cell differentiation in diseases characterized by disturbances in B-cell development. In fact, distinct types of abnormal Of interest, previous reports had already mentioned a decrease in IgD + CD27 + memory B-cell subset in patients with SLE [31] , primary SS [32] [33] [34] or SSc [35] . Also, a reduction in circulating memory B cells was demonstrated in patients with X-linked Hyper-IgM syndrome [36] , chronic granulomatous disease [37] and HIV infection [38] . Hence, lower levels of circulating memory B cells seem to be hallmark linked with chronic inflammation rather than an exclusive feature of autoimmune conditions. Furthermore, in a study performed by Hansen et al. [39] , it was shown that the generation of the peripheral B-cell memory subset in SS patients seems to be particularly affected by abnormalities in post-recombination events. Our observations suggest that changes in the B-cell memory subset also occur in very early stages of RA and other polyarthritis. In VERA patients, despite the clinical response induced by corticosteroids and MTX, no effect of these treatments was reflected in changes of IgD + CD27 + memory B-cell levels.
Since B cells differentiate into memory or plasma cells [26] , the reduced frequency of circulating memory B cells in both VERA patients and other early arthritis patients could be explained by a skewing towards plasma cell differentiation, or by an increase in naïve B-cell population, thus resulting in less memory B cells. However, in our study, we did not find any statistically significant difference in the frequencies of circulating plasma cells when comparing both VERA and VEA patients with controls, although we might not exclude the possibility of this B-cell subpopulation being increased in the bone marrow, where it mainly resides [40] , or in the rheumatoid synovium. Disturbances in the naïve B-cell subpopulation have been observed in other autoimmune conditions associated simultaneously with a decrease in circulating memory B cells. In fact, SS [34, 41] [43] , since long-term, low-dose corticosteroid therapy induces a decrease in B-cell counts [44] . However, our results indicate that short-term low doses of corticosteroids do not appear to affect B-cell counts. On the other hand, the effect of MTX on circulating blood cells in autoimmune conditions is controversial [45] [46] [47] . In a study performed by Bohm [48] , it was observed that SLE patients treated with short-term MTX had slightly increased levels of total CD3 
Conclusions
In summary, in the first few weeks of arthritis onset there seems to be an alteration in the frequency of circulating memory B cells, particularly pre-switch memory B cells, as compared with controls. In addition, the short-term use of corticosteroids and MTX does not seem to affect circulating B-cell subpopulations in the VERA patients. However, since other early arthritis patients, who did not fulfil the ACR criteria for RA, also had a decrease in pre-switch memory B cells before any treatment was started, it seems that this effect is not unique and specific to the initial phase of RA. Further studies are required for a better understanding of the biological meaning of the reduction in the memory B-cell pool in an early arthritis condition.
Rheumatology key messages
. In very early polyarthritis patients, there is a reduction in pre-switch memory B cells. . Short-term therapy with corticosteroids and MTX does not affect circulating B-cell subpopulations.
